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ABSTRACT Chronic Pseudomonas aeruginosa lung infections in cystic fibrosis (CF)
evolve to generate environmentally adapted biofilm communities, leading to increased
patient morbidity and mortality. OligoG CF-5/20, a low-molecular-weight inhaled algi-
nate oligomer therapy, is currently in phase IIb/III clinical trials in CF patients.
Experimental evolution of P. aeruginosa in response to OligoG CF-5/20 was assessed
using a bead biofilm model allowing continuous passage (45 days; ;245 generations).
Mutants isolated after OligoG CF-5/20 treatment typically had a reduced biofilm-form-
ing ability and altered motility profile. Genotypically, OligoG CF-5/20 provided no
selective pressure on genomic mutations within morphotypes. Chronic exposure to
azithromycin, a commonly prescribed antibiotic in CF patients, with or without OligoG
CF-5/20 in the biofilm evolution model also had no effect on rates of resistance acqui-
sition. Interestingly, however, cross-resistance to other antibiotics (e.g., aztreonam) was
reduced in the presence of OligoG CF-5/20. Collectively, these findings show no appa-
rent adverse effects from long-term exposure to OligoG CF-5/20, instead resulting in
both fewer colonies with multidrug resistance (MDR)-associated phenotypes and
improved antibiotic susceptibility of P. aeruginosa.
IMPORTANCE The emergence of multidrug-resistant (MDR) pathogens within biofilms
in the cystic fibrosis lung results in increased morbidity. An inhalation therapy derived
from alginate, OligoG CF-5/20, is currently in clinical trials for cystic fibrosis patients.
OligoG CF-5/20 has been shown to alter sputum viscoelasticity, disrupt mucin polymer
networks, and disrupt MDR pseudomonal biofilms. Long-term exposure to inhaled
therapeutics may induce selective evolutionary pressures on bacteria within the lung
biofilm. Here, a bead biofilm model with repeated exposure of P. aeruginosa to OligoG
CF-5/20 (alone and in combination with azithromycin) was conducted to study these
long-term effects and characterize the phenotypic and genotypic adaptations which
result. These findings, over 6weeks, show that long-term use of OligoG CF-5/20 does
not lead to extensive mutational changes and may potentially decrease the pathoge-
nicity of the bacterial biofilm and improve the susceptibility of P. aeruginosa to other
classes of antibiotics.
KEYWORDS cystic fibrosis, Pseudomonas aeruginosa, alginate oligosaccharide, biofilm,
bead model
Cystic fibrosis (CF) is an autosomal recessive disorder, affecting up to 1 in 2,500 livebirths (1), with higher incidence in the United States, Europe, and Australia (2). The
disease is characterized by mutations in the CF transmembrane conductance regulator
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(CFTR) gene, resulting in impaired functioning of epithelial chloride channels (3) and a
biochemically altered viscous mucus (4). CF is associated with recurrent lung infection
and chronic inflammation, which ultimately lead to impaired lung function and prema-
ture death (5). Prolonged antibiotic treatment has played a vital role in controlling CF
infections and contributed to the increasing median life expectancy of CF patients (6).
Chronic reliance on antibiotics by CF patients, however, produces considerable selective
pressures on the lung biofilm community. The opportunistic pathogen Pseudomonas aer-
uginosa typically colonizes the lungs of CF patients at 8.8 years old (7), where it then
undergoes considerable selective pressure from systemic and chronically inhaled antibi-
otics, the host immune system, and oxidative stress within the CF lung biofilm (8). The
inability of the immune response or long-term, high-dose, antimicrobial treatments to
totally eradicate P. aeruginosa is witness to the fitness advantage of this evolutionary
process (9).
The environmental stress stimuli in the CF lung are reflected in the extensive phe-
notypic and genotypic adaptations observed in CF P. aeruginosa populations (10). With
chronic colonization, later-stage bacterial isolates are distinctly different from pioneer
colonizers, displaying well-defined characteristics such as loss of motility, mucoidy,
reduced growth rates, increased antibiotic resistance, and defective quorum sensing
(QS) signaling (8). Furthermore, mutations in P. aeruginosa to the alginate-producing
mucoid phenotype or highly adherent small colony variants (SCVs) occur with
increased resistance to host defenses (11). Eventually, de novo mutations lead to evolu-
tion of antibiotic resistance in individual patients (12, 13), enabling the CF lung to
become colonized by multidrug-resistant (MDR) pathogens, particularly P. aeruginosa
(10). Of those patients positive for P. aeruginosa in 2018, 16.9% were reported by the
Cystic Fibrosis Foundation to carry MDR strains (https://www.cff.org/Research/Researcher
-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf).
A new CF inhalation therapy, OligoG CF-5/20, is currently in phase IIb/III clinical tri-
als in CF patients (www.ClinicalTrials.gov; identifiers NCT03698448 and NCT03822455).
OligoG CF-5/20 is a low-molecular-weight polydisperse alginate oligosaccharide (num-
ber average molecular weight [Mn], 3,200) shown to be well tolerated with no toxic/
adverse events in randomized, placebo-controlled, dose-escalation clinical trials. Lung
scintigraphic studies demonstrated a 38.6% deposition of the dry powder inhalation
(14). Ex vivo studies have also demonstrated the ability of OligoG CF-5/20 to alter the
viscoelastic properties and disrupt the complex mucin polymer networks of CF sputum
(14). Furthermore, OligoG CF-5/20 has been shown to possess antibiofilm properties
(15, 16) and enhance antibiotic activity (16, 17) against P. aeruginosa. Effects are medi-
ated via extracellular polymeric substance (EPS) disruption (15), inhibition of QS signal-
ing (18), and alteration of bacterial surface charge and motility (17, 19).
While antimicrobial susceptibility testing is predominantly based on laboratory cul-
ture of planktonically growing bacteria, it has become increasingly clear that localized
chronic infections are principally the result of intractable bacterial biofilms (20). With
antimicrobial resistance in biofilms being up to 1,000-fold greater than that of plank-
tonically growing isogenic strains (21), biofilm models have been increasingly employed
to examine bacterial evolutionary pathways. Within CF, biofilm models incorporate
many of the characteristics of a CF lung ecosystem, with slow growth in an entangled
polymeric network, facilitating horizontal gene transfer between MDR bacteria, which
can withstand repeated antimicrobial dosing (22). A number of biofilm evolutionary
models have been reported in the literature (23) with the complex structure of the bio-
film environment demonstrating increased ecological diversity and productivity (24). In
the present study, a bead biofilm model was used that incorporated regular cycles of
surface colonization, biofilm assembly, and dispersal. Importantly, in vitro long-term evo-
lution experiments such as bead biofilm models have been shown to mimic P. aerugi-
nosa adaptation in the CF lung (10, 25, 26).
We have previously shown that planktonic subculture of P. aeruginosa (PAO1) for
21 days in escalating concentrations of OligoG CF-5/20 did not result in loss of
Oakley et al.
January/February 2021 Volume 6 Issue 1 e01216-20 msphere.asm.org 2








antimicrobial activity (17). The present study aimed to determine the effects of pro-
longed exposure of P. aeruginosa biofilms to OligoG CF-5/20 with regard to the
evolved genotypic and phenotypic characteristics of different colony morphotypes to
determine impact on bacterial evolution. This study also determined the acquisition of
resistance to azithromycin (AZM) (an antibiotic commonly used in the treatment of CF)
in the presence and absence of sublethal concentrations of OligoG CF-5/20 (27).
Positive impacts of selective pressure on biofilm growth (negative impact for the host)
by OligoG CF-5/20 might be expected to manifest themselves by increased develop-
ment of SCVs and mucoid phenotypes, both of which are associated with increased re-
sistance to antimicrobial therapy. This study, however, demonstrates that OligoG CF-5/
20 exposure did not cause extensive mutational changes in P. aeruginosa but instead
appeared to reduce both MDR-associated phenotypes and prevalence of antibiotic-
resistant phenotypes. The mechanisms underpinning this are explored.
RESULTS
Prolonged exposure of P. aeruginosa to OligoG CF-5/20 results in decreased
morphotype diversity. A bead biofilm model was employed with Pseudomonas aeru-
ginosa (PAO1)with or without 2% OligoG CF-5/20 over 45 days (Fig. 1) (see Materials
and Methods). Briefly, biofilms were formed on the surface of beads in wells containing
FIG 1 Schematic showing the bead biofilm model experimental strategy. (A) Modeling of prolonged exposure
to OligoG CF-5/20 and azithromycin exposure. (B) Corresponding experimental design flowchart (AZM; azithromycin).
Biofilms were grown on sterile 7-mm-diameter borosilicate glass beads with yellow and blue beads used for alternate
transfer days.
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growth mediumwith or without 2% OligoG CF-5/20. On passage days, biofilm-covered
beads were transferred into a new well containing fresh medium (6 2% OligoG CF-5/
20) alongside a new sterile bead. The bacteria from the mature biofilm community
would then colonize the new sterile bead, to repeat the transfer sequence again. The
“old” beads were either discarded or used for sampling on transfer days 21 and 45
(Fig. 1A).
As a defined core set of SCV genes has yet to be documented (and with commonal-
ity between phenotypic and genotypic changes within different SCV populations not
always apparent), for the purposes of this study SCVs were defined as pinpoint colonies
formed within 72 h (,1mm in diameter) (28). Individual bacterial colony morphotypes
were characterized according to size ([a] small [pinpoint], ,1mm; [b] medium, 1 to
3mm; and [c] large, .3mm) and surface texture (Fig. 2A), as well as opacity, mucoidy,
and colony margin (see Table S1 in the supplemental material). Phenotypic characteri-
zation of the biofilm-evolved monoculture isolates (identified within the agar plate)
revealed that 40 different morphotypes were evident across the study as follows from
4 biological repeats: day 21 control, 13 isolates; day 21 OligoG CF-5/20, 12 isolates; day
45 control, 10 isolates; and day 45 OligoG CF-5/20, 5 isolates (Table S1).
Half of all morphotypes proved to be medium-sized colonies which were less fre-
quently isolated in the OligoG CF-5/20-treated samples at day 21 (Fig. 2B). Only a small
FIG 2 Prolonged exposure of P. aeruginosa results in decreased morphotype diversity. (A) Appearance of representative single-colony
morphologies on blood agar plates from control and 2% OligoG plates, shown to scale (small [pinpoint], ,1mm; medium, 1 to 3mm; large,
.3mm). Comparison of biofilm beads exposed to 0% and 2% OligoG over 21 and 45 days. (B) Categorizing numbers of morphotypes (small,
medium, and large colonies) isolated from each growth condition. (C) Subcategorizing surface textures of small, medium, and large colonies
(n= 4).
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proportion were large morphotypes, with none seen by day 45 in the 2% OligoG CF-5/
20 samples. A decrease in morphotype diversity was evident in both the control and
OligoG CF-5/20-treated group by day 45. SCVs were evident across the study, with
fewer morphotypes seen from days 21 to 45 in both control and treated groups.
Characterization of SCVs. A total of 12 different small colony variant (SCV) mor-
photypes were isolated from the samples. One biological repeat had no SCVs in either
the control or the OligoG CF-5/20 sample at any time point (Table S1). The remaining
three biological repeats demonstrated a reduction in SCV morphotype diversity, with 1
smooth SCV morphotype isolated at day 45.
The surface textures of the SCVs were more variable at day 21 than at day 45
(Fig. 2C), being ruffled and studded in the control samples and smooth and ruffled in
the 2% OligoG CF-5/20-treated samples at day 21. These characteristics were lost by
day 45, with all clones demonstrating smooth colony morphologies. In contrast, the
medium-sized colonies demonstrated both smooth and studded colonies at day 21,
which actually became more diverse by day 45 for both control (smooth, ruffled, and
studded) and OligoG CF-5/20 (ruffled, studded, and wrinkled) samples. The majority of
the large phenotypes isolated over the duration of the study were smooth.
Prolonged treatment of PAO1 with OligoG CF-5/20 reduces the biofilm-forming
ability of small and medium-sized morphotypes. The morphology of biofilms pro-
duced by the different morphotypes evolved during the bead biofilm model was inves-
tigated using scanning electron microscopy (SEM), crystal violet (CV) biofilm assays,
and confocal microscopy (n=3). Untreated control samples were visualized under SEM,
according to their subclassification (at 21 days). Small, ruffled, and studded clones
demonstrated formation of medium to large biofilm microcolonies, with the former
subtype also forming EPS-encased biofilms bound to the glass surface (Fig. 3A).
Medium-sized clones formed small clusters of microcolonies, interlinked with branch-
ing cells. The smooth mucoidal subtype did not attach strongly to the glass surface,
while the studded subtype produced a combination of spherical microcolonies and
more flat homogenous biofilms attached to the glass surface. Large clones demon-
strated a similar monolayer biofilm to that found in the wild-type (WT) PAO1, although
the cells appeared more rounded in shape.
The crystal violet (CV) binding assay (29, 30) highlighted the inherent variability
between the biofilm-forming abilities of the different morphotypes (Fig. 3B). The large
colonies showed similar values to that of the WT (P. 0.05). The medium-sized colonies
in the control samples had an increased biofilm-forming ability compared to those
found in the OligoG CF-5/20-treated samples at day 21 and day 45. The majority of the
treated and untreated SCVs demonstrated an increased biofilm-forming ability com-
pared to the WT. The day 45 SCV isolated from the OligoG CF-5/20-treated sample con-
trarily exhibited a statistically significant reduction in its biofilm-forming ability (P, 0.05,
Fig. 3B).
Confocal laser scanning microscopy (CLSM) of 24-h biofilm-grown SCVs (LIVE/DEAD
stained) highlighted the variability evident between the biofilm forming abilities of
SCVs (Fig. 3C). Biofilms formed from the small smooth morphotypes at day 45 demon-
strated a less dense and sparser biofilm in the treated samples than in the untreated
control, confirming the findings in the CV assay.
Altered motility profile of the OligoG CF-5/20-treated morphotypes. SCVs and
medium colonies isolated at day 21 (Fig. 4A) and day 45 (Fig. 4B), from both control
and OligoG CF-5/20-treated samples, were found to have reduced motility (particularly
swarming ability) compared to the WT PAO1 control (Fig. 4A and B). These reductions
were more noticeable for the day 45 morphotype isolates, where even the large colo-
nies showed a reduction in motility. Swarming motility was largely unchanged for all
isolates at both time points, remaining similar to that of the WT control (Fig. 4A and B).
Unlike the other isolates, the SCV morphotype in the 2% OligoG CF-5/20-treated sam-
ples at day 45 surprisingly demonstrated an increase in swimming motility (Fig. 4C).
However, none of these trends reached statistical significance in motility changes
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between WT PAO1 control and the morphotypes (control and OligoG CF-5/20-treated
samples; P. 0.05).
Genetic diversity of PAO1 isolates evolved in OligoG CF-5/20 demonstrates no
evidence of adverse selective pressure. Genome resequencing was performed to
determine genetic changes associated with the evolution of PAO1 biofilm populations,
with or without exposure to 2% OligoG CF-5/20. Overall, 96 mutations (single nucleo-
tide polymorphisms [SNPs], insertions, deletions, duplications) were identified across
38 bead biofilm-evolved isolates, with twoday 21 transfer isolates (C10a and O6a) hav-
ing no evidence of genomic mutation. Eight mutations were in noncoding regions,
FIG 3 Prolonged exposure to OligoG CF-5/20 alters the biofilm-forming ability of the colony morphotypes. (A) Biofilm-forming ability of
selected morphotypes from control samples using scanning electron microscopy (day 21; bar, 10mm). (B) Crystal violet quantification of
biofilm-forming ability of all morphotypes from control and 2% OligoG CF-5/20 biofilm wells (24 h). (C) Confocal laser scanning microscopy
imaging of selected SCV biofilms (LIVE/DEAD stained; bar, 20mm) (*, P, 0.05; n= 3).
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while 88 were in coding regions. The 8 mutations in noncoding regions were all identi-
fied in control day 45 transfer isolates (C1b, C2b, and C3b) and excluded from the over-
all “functional” analysis. The 88 muations in coding regions represented 39 unique
changes, affecting 21 coding regions (see Table S2 in the supplemental material). Only
five mutations were synonymous, 1 was found in the tssL1 gene in the isolate C3b, and
two mutations were found in a gene encoding a hypothetical bacteriophage-associ-
ated protein in two isolates, C1b and C2b. Analysis of the distribution of the 88 muta-
tions revealed that there was a significantly higher number of mutations in the day 45
transfer isolates than the day 21 transfer isolates (control, day 21 versus day 45,
P=0.02; OligoG CF-5/20, day 21 versus day 45, P=0.02). There was no difference, how-
ever, in the numbers of mutations observed between control and OligoG CF-5/20-
exposed isolates (control versus OligoG CF-5/20, day 21, P=0.28; day 45, P=0.90).
Genes that had acquired mutations in the evolved isolates were clustered according
to function (Table 1). The majority of mutations occurred in genes associated with sig-
nal transduction (n=32) or transcription (n=39) and genes encoding hypothetical or
bacteriophage-associated hypothetical proteins (n=8), with smaller numbers of muta-
tions linked to motility (n=5), secretion (n= 1), and translation (n=3). Several genes in
the signal transduction and transcription functional categories were found in pathways
involved in biofilm formation, chemotaxis, motility, and QS. Apart from the mvfR and
mexT transcriptional regulators and the wspF methyltransferase involved in signal trans-
duction, no other genes were found to have mutations in isolates from all four popula-
tions. Notably, acquired mutations in motility genes were present only, in both control
and OligoG CF-5/20-treated isolates, at day 45.
Chronic exposure to OligoG CF-5/20 and azithromycin reduces the acquisition
of resistance to other classes of antibiotics. The macrolide azithromycin (AZM) is of-
ten prescribed for prolonged use in patients colonized with chronic P. aeruginosa due
to its anti-inflammatory effects (27). In a parallel experiment, the effect of the antibiotic
FIG 4 Changes in the motility of control and 2% OligoG CF-5/20 morphotypes. Radar chart demonstrating median twitching,
swimming, and swarming motility (millimeters) compared to WT control. (A) At day 21. (B) At day 45. (C) Example of swarming
motility plates for small, medium, and large colonies. (No large colonies were isolated from OligoG CF-5/20 cultures at day 45.)
n=3.
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AZM (in the presence and absence of 2% OligoG CF-5/20) was also examined in the
bead model over 45 days (Fig. 1B).
The enriched mixed populations (using the day 21 biofilm beads cultured for 24 h
in fresh medium) were tested for cross-resistance against a range of antibiotics com-
monly used in CF or representatives of different classes of antibiotics with different
mechanisms of action (n=10). Antibiotics targeting key CF pathogens (including chronic
P. aeruginosa) used within the cross-resistance study were comprised of azithromycin
(macrolide) (27), ciprofloxacin and levofloxacin (quinolones), colistin (polymyxin E), and
aztreonam (monobactam) and tobramycin (aminoglycoside). As cephalosporins, carba-
penem, rifamycin, and tetracyclines are also routinely used for CF treatment, ceftazidime,
meropenem, rifampin, and oxytetracycline, respectively, were also employed in the
cross-resistance studies (31).
Prolonged exposure of PAO1 (grown in the presence and absence of 2% OligoG
CF-5/20) demonstrated no change in resistance to azithromycin, both values being
TABLE 1 Distribution of mutations in evolved genotypesa
aThe heatmap indicates the numbers of mutations in genes belonging to different functional groups, as per the
Pseudomonas Genome Database. The color intensity reflects the frequency of mutations in each population
(actual values also given inside the boxes). Populations are indicated at the top of the figure: control and OligoG
CF-5/20 at transfer days 21 and 45. Links to functional pathways are given in parentheses next to gene
identifications: BF, biofilm; CH, chemotaxis; M, motility; QS, quorum sensing; and MDR, multidrug resistance.
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32mg/ml. However, subculturing at sub-MIC levels of AZM (8mg/ml) in both the pres-
ence and absence of 2% OligoG CF-5/20 resulted in an increase in MIC values from
32mg/ml to 256mg/ml at day 21 (Table 2). This resistance to AZM (6 OligoG CF-5/20)
was retained for up to 6 subsequent transfers (with no antibiotics) following comple-
tion of the 45-day experiment.
Samples grown in Mueller-Hinton (MH) broth only or 2% OligoG CF5-/20 demon-
strated no change in resistance to other classes of antibiotics (Table S3). Biofilms grown
in AZM with 2% OligoG CF-5/20 demonstrated a decrease (up to 3-fold) in resistance
(MIC) to antibiotics such as aztreonam and oxytetracycline compared to biofilms
growth in AZM alone (Table 2).
DISCUSSION
Large-scale evolutionary research has provided extensive evidence on the transition
of P. aeruginosa from opportunistic to primary pathogen in the CF lung (13). P. aerugi-
nosa lung infections typically progress clonally following infection, often with a single
environmentally acquired genotype (10). Over the course of long-term chronic CF
infection, clonal populations undergo considerable phenotypic and genetic adaptation
to the lung environment (8, 32) alongside widespread biofilm formation (33). We used
the biofilm bead model to mimic this long-term, adaptive process in vitro, to assess the
phenotypic and genotypic changes in P. aeruginosa biofilm populations following pro-
longed treatment with the antimicrobial agent OligoG CF-5/20.
In vitro short-term experiments (up to 7days) have shown that biofilm communities
undergo extensive diversification (32), but paradoxically, our study showed that this was
not evident over the longer term. The demonstration here of decreased morphotype di-
versity present in our biofilm-bead model at day 45 more closely reflects the findings of
in vivo studies showing limited diversification of the evolving P. aeruginosa lineage (13). It
has been hypothesized that within biofilm communities, bacteria are effectively exposed
to lower (sublethal) concentrations of antibiotics (leading to low-level mutation rates)
than bacteria growing planktonically (34). Taken together, these findings support the va-
lidity of the bead model, as it appears to closely mimic the in vivo situation.
SCVs are readily isolated from CF lung-adapted P. aeruginosa populations; having
been associated with poor clinical outcome in CF patients (35) and the persistence of
infection in animal models (36). Whether they are etiologically involved in the disease
process or just preferentially associated remains unclear (11). In vitro biofilm studies
have previously shown the rapid emergence of SCVs in P. aeruginosa within a 5-day
biofilm grown in a drip flow reactor (32). We observed the emergence of SCVs within
21 days. However, cultures containing SCVs had decreased by day 45. SCVs are charac-
terized by their slow growth (37) and hyperdetachment phenotype (32). Mutations
such as hyperdetachment can enable bacteria to escape environmental stresses, (e.g.,
antibiotic treatment and nutrient limitation), enhancing dissemination and coloniza-
tion of communities (13). Samples subcultured in the presence and absence of OligoG
CF-5/20 exhibited fewer SCVs by day 45 than by day 21; however, the only SCV isolated
from the OligoG CF-5/20-treated samples at 45 days had a reduced biofilm-forming
ability and increased motility. The phenotypic behavior of the SCV formation following
growth in OligoG CF-5/20 may have significant clinical advantages for the CF population.
TABLE 2 The effect of OligoG CF-5/20 on the acquisition of resistance to azithromycin (AZM)
on the whole bacterial population at day 21a
Treatment AZM CAZ CIP Oxy-TET LEV COL ATM MER RIF TOB
AZM 256 512 8 128 8 1 8 2 64 0.5
AZM and 2% OligoG 256 128 4 16 4 0.25 1 0.5 64 1
aData are MIC values (mg/ml) of cross-resistance to other classes of antibiotics. Antibiotics used: CAZ,
ceftazidime; CIP, ciprofloxacin; AZM, azithromycin; Oxy-TET, oxytetracycline; LEV, levofloxacin; COL, colistin;
ATM, aztreonam; MER, meropenem; RIF, rifampin; TOB, tobramycin. Decrease in antimicrobial activity (MIC) is
indicated by shaded areas.
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Studies have previously shown that subcultured biofilm populations diversified into
smooth/studded (S), ruffled spreader (R), and wrinkly (W) phenotypes (24). While pro-
longed transfer led to a decrease in the ruffled spreader and wrinkly phenotypes, it has
been hypothesized that smooth phenotypes may persist (24), a trend observed here in
the surface texture of the SCVs from both control and OligoG CF-5/20-treated biofilm
samples. Even without antibiotic selection, biofilm drip flow reactor model studies,
using various PAO1 mutants (and clinical CF isolates), produced a variety of colony var-
iants similar to those observed in the reference strain, likely due to spontaneous, recA-
dependent, recombination events (increasing the competitive advantage of the bio-
film-growing cells to resist environmental stress) (32).
Changes in motility phenotype have previously been observed early in biofilm cul-
ture (at 5 days), which have been hypothesized to be caused by multiple genetic
changes (32). Our finding of reduced motility of all pseudomonal SCVs (compared to
the WT PAO1) observed at day 21 has previously been demonstrated (38). However, at
45 days, the single OligoG CF-5/20-treated biofilm SCV isolate retained its ability to
swim and had a reduced biofilm-forming ability, indicating that it did not appear to
behave like a “typical” SCV.
The spectrum of mutations observed in the biofilm isolates is consistent with previ-
ous work on P. aeruginosa. All but five of the observed mutations were nonsynony-
mous, reflecting that adaptation to the biofilm lifestyle proceeds via higher propor-
tions of nonsynonymous mutations (39, 40). Similar nonsynonymous mutations have
been noted in vivo in Burkholderia dolosa where adaptive evolution in parallel was also
demonstrated, in multiple individuals (41). In vivo studies (undertaken over 35 years)
have shown that phenotypic changes in the bacterial CF biofilms decrease with time,
while genotypic changes were found to be more consistently linear over the same
time period (13). Furthermore, in vivo CF-evolved phenotypes have shown a discordant
relationship between phenotypic characteristics when multiple isolates from the same
sample were tested, and even colonies categorized as the same morphotype have
been shown to display different antimicrobial susceptibility profiles (42). It is perhaps
unsurprising that the separate in vitro cultures have evolved divergently, as in vivo, P.
aeruginosa bacteria inhabiting different lobes of the CF lung have been shown to pos-
sess diverse and different phenotypes (43).
Of the 6 signal transduction genes that had acquired mutations, five (bifA, yfiR,
wspA, wspF, and morA) were linked to regulation of intracellular cyclic-di-GMP levels,
being closely involved in the transition from motile to sessile lifestyles (44). In particu-
lar, both wspF and morA have been implicated in colony morphology changes (wrin-
kled colonies and SCVs) and biofilm adaptation in P. aeruginosa (45). In isolates from
the day 45 transfer populations, genes directly related to motility including type IV pili
(pilY1, pilM, and pilT) were mutated, as has been observed previously in P. aeruginosa
PAO1 biofilm models (34, 40). Overall, the majority of mutated genes were linked to
pathways involved in biofilm formation, chemotaxis, motility, and QS pathways, cor-
roborating the results of other studies and the pathoadaptive mutations frequently
observed in P. aeruginosa within the CF lung (12, 46).
Experimental evolutionary studies have investigated genomic mutation in P. aerugi-
nosa following exposure to antibiotics such as ciprofloxacin and demonstrated a signif-
icant increase in the number of mutations in both planktonic and biofilm populations
(34), as well as in populations modeled in synthetic CF sputum medium (45). These
studies found mutations in genes specifically linked to ciprofloxacin exposure (Mex
efflux systems, DNA gyrases) and genes associated with adaptation to a CF-like envi-
ronment (QS, motility, cyclic-di-GMP signaling). While we observed mutations in the
mexT gene, a multidrug efflux transcriptional regulator (47), these occurred across all
populations. Moreover, while a significant increase in the number of mutations was
observed between day 21 and day 45 transfer populations, these were similar in con-
trol and OligoG CF-5/20-exposed isolates. Furthermore, there were no mutated genes
in functional gene categories exclusive to OligoG CF-5/20-exposed isolates, the same
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categories being affected in both control and OligoG CF-5/20-exposed populations.
From this prolonged exposure experiment, we conclude that, unlike the antibiotics
tested, OligoG CF-5/20 did not drive mutations in specific genes, during the adaption
of P. aeruginosa PAO1 to biofilm growth.
Clearly, these experiments lack the highly selective and heterogeneous local envi-
ronmental stressors (e.g., oxidative and osmotic stress) found in the CF lung (48), which
are important in bacterial evolution (10). However, clinical studies have highlighted
sampling variability and microbial diversity due to CF lung compartmentalization, mak-
ing analysis of clinical samples difficult (49). Clark et al. also showed that the abun-
dance of individual morphotypes fluctuated with time, no single morphotype predomi-
nating in the 12 samples collected over a 12-month period and considerable phenotypic
variability being observed in isolates from individual sputum samples (42). The advant-
age of laboratory models such as the bead model used here is therefore apparent, being
able to produce reproducible biofilms under controlled conditions.
The effect of prolonged exposure to commonly utilized antibiotics at sub-MIC levels
positively selects for resistant bacteria (50). Clinical studies have shown rapid shifts in
antimicrobial susceptibility profiles within short periods of time (as short as 7 days) fol-
lowing antibiotic administration (32). A clear trend of increased antibiotic resistance
over time is also evident within the CF lung microbiome, although considerable intra-
and intersample diversity in susceptibility to specific antibiotics is evident (42). Resistance
to antibiotics such as aztreonam and ceftazidime was found to be moderately correlated,
with discontinuation of aztreonam therapy reducing susceptibility to ceftazidime, and also
to ciprofloxacin in individual isolates (42). A parallel study of laboratory adaptation of
Escherichia coli to various antibiotics over 90days demonstrated that acquisition of resist-
ance to a single antibiotic can alter susceptibility to a range of other antibiotics (51).
The mutations incurred can also compensate for fitness cost associated with the ac-
quisition of resistance. Mutants formed in the presence of azithromycin within this
study demonstrated altered susceptibility to other classes of antibiotics. This highlights
a possible alternative mode of action for mutations arising in the presence of OligoG
CF-5/20, where P. aeruginosa was rendered more susceptible to antibiotics such as
aztreonam and oxytetracycline. We have previously observed antibiotic potentiation
with OligoG CF-5/20 in planktonic culture (16, 17). This study confirmed that the pres-
ence of OligoG CF-5/20 did not alter the acquisition of resistance to azithromycin
within these biofilms when assessed at day 21. These findings suggest that bacteria
growing in vitro in the presence of OligoG CF-5/20 have fewer colonies with MDR-asso-
ciated phenotypes and improved antibiotic susceptibilities, which may afford signifi-
cant clinical benefits in patients treated with this novel antibiofilm therapy.
MATERIALS ANDMETHODS
Bacterial strain and culture conditions. Pseudomonas aeruginosa (PAO1, ATCC 15692) was used
throughout the study. Overnight cultures (n= 4) were prepared in tryptone soy broth (TSB; LabM) using
an inoculum from bacteria freshly cultured on blood agar plates (BA; Blood agar base no. 2; LabM), and
all experiments were performed in Mueller-Hinton (MH) broth (LabM).
Alginate oligosaccharide (OligoG CF-5/20). OligoG CF-5/20 was produced from the stem of the
brown seaweed Laminaria hyperborea and provided by AlgiPharma AS (Sandvika, Norway), as previously
described (17). OligoG CF-5/20 has a high guluronate content (.85%) and a mean degree of polymeriza-
tion (DPn) of 16.
MIC assay. MIC assays were performed using a broth microdilution method in MH broth as previ-
ously described (17) in accordance with standard guidelines (52).
Bead biofilm evolution model. The bead model used here was adapted from a previous study (24)
(Fig. 1A). Biofilms were grown on sterile borosilicate glass beads (7-mm diameter; with yellow and blue
beads used for alternate transfer days) which were placed in each of well of a 24-well microtiter plate
containing 1ml MH broth plus or minus 2% OligoG CF-5/20 (n= 4 for each condition/control). Plates
were incubated continuously at 37°C (20 rpm) for the duration of the experiment, On passage days, the
beads were transferred into the corresponding wells of a fresh 24-well plate 3 times/week, which con-
tained a single new sterile bead (in each well), with the old bead being discarded. On days 21 and 45,
however, the old bead was removed from each well and used to inoculate 10ml sterile TSB for overnight
growth at 37°C.
At time zero, one bead was placed in each well in an inoculum of WT PAO1 of 5 104 CFU/ml.
However, assuming that planktonic cells decline over time (by up to 33%) (24) due to an increase in the
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number of cells attaching to the bead, the number of generations was estimated at 16 log2(dilution),
giving an estimate for generations over the course of the experiment between 240 and 250. Each plate
contained a sterile MH broth control. Purity plates were performed weekly on each test well on BA
plates. At days 21 and 45, purified morphotypes were frozen at 280°C on microbank beads to be used
for subsequent morpho- and genotyping experiments.
Phenotypic characterization of colony morphotypes. The “old” bead was removed, vortexed in
fresh TSB, and grown overnight before samples were plated out onto blood agar and incubated for 24
to 72 h before purifying individual colonies on fresh BA plates and freezing them for later use. The col-
ony morphotypes isolated (MH6 2% OligoG CF-5/20) were reviewed independently by two researchers
at both day 21 and day 45 to ensure consistency of morphological identifications.
Scanning electron microscopy (SEM). A selection of different morphotypes in relation to size and
surface textures was made from the control sample at day 21 (small ruffled, small studded, medium
smooth [mucoid], medium studded, and large smooth) and a WT PAO1 control. Overnight cultures of
individual morphotypes were adjusted to 106 CFU/ml in MH broth and grown for 24 h in a 12-well plate
(Greiner Bio-One) on glass slides (37°C; 20 rpm). Following incubation, the supernatant was removed,
and biofilms were fixed with 2.5% (vol/vol) glutaraldehyde prior to being washed (4 times) with distilled
water (dH2O) and freeze-dried. Samples were gold coated and imaged using a Tescan Vega conventional
scanning electron microscope (SEM; 6 kV).
Biofilm formation crystal violet assay. All morphotypes from day 21 and day 45 were tested for
biofilm-forming ability in 96-well polystyrene plates and compared to the WT PAO1 control. Biofilms
were grown in a flat-bottomed 96-well plate (5 105 CFU/ml in MH broth) for 24 h statically (n= 3 bio-
logical, n= 5 technical repeats) and quantified using an adapted crystal violet (CV) methodology (29, 30).
The plates were gently washed (twice) in dH2O (for 10 s) to remove planktonically growing cells prior to
adding 0.1% CV (125ml) into each well to stain the attached cells. Following a 15-min incubation at
room temperature, plates were rinsed in dH2O (4 times) and allowed to dry for$1 h, prior to solubilizing
the dye in 95% ethanol (200ml for 30 min). A total of 125ml per well was removed to a fresh 96-well
plate, and the absorbance (optical density at 550 nm [OD550]) was measured with a spectrophotometer.
Confocal laser scanning microscopy (CLSM) imaging of SCVs. Individual isolates representing
smooth and ruffled small colonies from the SCVs were chosen from biofilm monocultures obtained on
day 21 and day 45 (control and 2% OligoG CF-5/20 plates). When multiple samples were available,
clones with the best biofilm production were selected. Overnight cultures were prepared in TSB from
the freezer stock (37°C; 120 rpm). CLSM was performed on biofilms grown in Grenier 96-well glass-bot-
tomed plates in MH broth using a starting inoculum of 106 CFU/ml (37°C; 24 h). Supernatant was
removed before staining the cells with 6% (vol/vol) LIVE/DEAD (BacLight bacterial viability kit;
Invitrogen) stain in phosphate-buffered saline (PBS) for 10 min, prior to imaging with a Leica SP5 confo-
cal microscope with 63 magnification under oil.
Motility assays. All morphotypes from day 21 and day 45 were tested for swimming, swarming, and
twitching ability compared to the WT PAO1 control. Agar plate-based assays were prepared, and assay
mixtures were poured and used immediately once set, as previously described (53). Overnight cul-
tures were prepared from freezer stocks in TSB, and cells were point inoculated with a sterile tooth-
pick onto the surface of the agar prior to being incubated for 48 h at 25°C (swimming) or 30°C (swarm-
ing) and 72 h at 30°C (twitching). Motility was determined as the widest diameter of bacterial migration
(millimeters).
Genotypic characterization of colony morphotypes. Whole-genome sequencing was performed
following genomic DNA extraction from wild-type P. aeruginosa PAO1 and evolved PAO1 isolates using
the Maxwell instrument and Maxwell 16 tissue DNA purification kits (Promega) according to the manu-
facturer’s instructions. Briefly, 3ml of fresh overnight culture was pelleted by centrifugation, and the pel-
let was resuspended in 300ml 4 M UltraPure guanidine isothiocyanate (ThermoFisher Scientific) and
added directly into the DNA purification kits. Eluted DNA was stored at 220°C. Whole-genome sequenc-
ing was performed at the Cardiff School of Biosciences Genomics Research Hub. DNA was prepared for
sequencing using the NEBNext Ultra II DNA library prep kit for Illumina and NEBNext multiplex oligo-
nucleotides for Illumina (New England BioLabs Inc.). Sequencing was carried out on an Illumina
NextSeq500 using a NextSeq 500/550 Mid Output v2 kit (300 cycles), giving, on average, 135-bp
paired-end reads. Approximately 2.9 million reads (range: 2.5 to 3.4 million) were yielded per sam-
ple, corresponding to an average coverage depth of approximately 125 (range: 106 to 142).
Bioinformatic analysis of whole-genome sequencing data. Bioinformatic analysis was carried out
on a virtual machine, hosted by the Cloud Infrastructure for Microbial Bioinformatics (CLIMB) consortium
(54). Quality control and Illumina adapter trimming of the raw sequencing reads were performed using
FastQC v0.11.5 (55) and Trim Galore! v0.4.3 (56) for paired-end reads. Genome assembly for the PAO1
WT was achieved using Unicycler v0.4.7 (57) with SPAdes v3.11.0 (58) and the option for short-read as-
sembly. Assembly quality was visualized with Bandage assembly graphs (59) and with QUAST v4.6.3 (60)
to determine that the PAO1 wild type shared .98.8% genomic DNA with the P. aeruginosa PAO1 ATCC
15692 sequence (GenBank accession number GCA_001729505.1). Contig ordering to the P. aeruginosa
PAO1 ATCC 15692 sequence was performed using ABACAS v1.3.1 (61). The resulting draft genome
sequence was annotated with Prokka v1.12 (62).
Polymorphic sites in the evolved PAO1 isolates were identified using Snippy v3.2 (63) with the
draft genome sequence of the wild-type PAO1 as the reference. For variant calling, the default param-
eters of minimum base quality of 20, minimum read coverage of 10, and 90% read concordance at
each locus were used. Only variants in the annotated coding regions were included in the analysis.
Variants identified in the wild-type PAO1 sequence reads were subtracted from all other evolved
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PAO1 isolates. Correct annotation of coding sequences containing variants was confirmed using the
BLASTN search tool of the Pseudomonas Genome Database (64) against the P. aeruginosa PAO1 ref-
erence sequence. Functional information for coding sequences was derived from the Pseudomonas
Genome Database.
Acquisition of resistance in the presence of azithromycin. The rate of acquisition of resistance to
azithromycin (AZM) at a sublethal concentration 2-fold lower than the MIC level (AZM; 8mg/ml) was con-
ducted in the presence and absence of 2% OligoG CF-5/20 using the biofilm bead model (Fig. 1A). Glass
beads were placed in 1ml AZM (8mg/ml)with or without 2% OligoG CF-5/20 in 24-well plates prior to
inoculation with PAO1 cultures (5 104 CFU/ml; n= 4) and incubated (80 rpm; 37°C). Beads were trans-
ferred into the corresponding wells in a fresh plate 3 times/week (Fig. 1A) for 45 days. Purity plates
were performed weekly on each test well on blood agar (BA) plates. At days 21 and 45, samples were
taken from all wells and frozen at 280°C on microbank beads to be used for cross-resistance studies.
Cross-resistance study. The enriched mixed populations grown in the presence and absence of 2%
OligoG CF-5/20 (6 AZM) were tested for cross-resistance against a range of antibiotics commonly used
(ceftazidime [CAZ], ciprofloxacin [CIP], azithromycin [AZM], oxytetracycline [oxy-TET], levofloxacin [LEV],
colistin [COL], aztreonam [ATM], meropenem [MER], rifampin [RIF], tobramycin [TOB]). The day 21 biofilm
bead cultures were vortexed in fresh medium and grown overnight (37°C; shaken). Cross-resistance was
tested using an MIC assay (broth microdilution method) as previously described (17). These were con-
ducted for the 4 biological repeats.
Loss of resistance. Following day 45 of transfer for the AZM study, the stability of AZM resistance
was analyzed by transferring beads into MH broth or MH broth with 2% OligoG CF-5/20 for a further
six transfers. Biofilm growths from each transfer were subcultured onto LB plates with or without
AZM (32mg/ml), and resistance to AZM was recorded if there was growth on the plates after 24 h.
Statistical analysis. The significance of the crystal violet biofilm assay data was assessed using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison post hoc test using Graph
Pad Prism 8. The motility assay data were analyzed using a nonparametric Kruskal-Wallis test performed
on IBM SPSS followed by a post hoc adjustment by the Bonferroni correction. Statistical analyses for the
genotypic characterization were performed using R statistical software (65) to determine differences
between the numbers of mutations in coding regions observed in each population (Control 21 days,
Control 45 days, OligoG CF-5/20-exposed 21 days and OligoG CF-5/20-exposed 45 days). As the num-
bers of mutations in all populations were found to be nonnormally distributed (Shapiro-Wilk test)
with equal variances (Levene’s test), a nonparametric Kruskal-Wallis test with post hoc pairwise com-
parisons using the Wilcoxon rank sum test and Benjamini-Hochberg adjustment was used to deter-
mine differences between the population medians. Differences were considered significant for
P# 0.05.
Data availability. Data generated and analyzed during this study are included in this published arti-
cle and its supplemental material. Sequence data supporting the genomic analysis have been deposited
in the European Nucleotide Archive with the accession code PRJEB36146 (ERP119298). Additional details
are available upon reasonable request.
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TABLE S1, DOCX file, 0.4 MB.
TABLE S2, DOCX file, 0.03 MB.
TABLE S3, DOCX file, 0.05 MB.
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